Home›Stock Screener›Marksans Pharma›Quarterly Results

Marksans Pharma Quarterly Results

Latest Quarter Net Profit
₹144 Cr
QSept 2026
Quarterly Results

Marksans Pharma quarterly results. In Sept 2026, Marksans Pharma (MARKSANS) reported revenue ₹958 Cr and net profit ₹144 Cr — revenue +29.1% YoY. Also explore Marksans Pharma share price performance to track price trends across different timeframes.

MARKSANS Quarterly Results — Revenue, Profit & EPS Highlights

Marksans Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View MARKSANS 52-week chart for the annual high/low range and current price position.

  • Revenue of ₹958 Cr in Sept 2026 (+7.5% vs Mar 2026, +29.1% vs Sept 2025)
  • Net Profit of ₹144 Cr in Sept 2026 (-3.4% vs Mar 2026, +45.5% vs Sept 2025)
  • EBITDA of ₹232 Cr in Sept 2026 (+0.4% vs Mar 2026)
  • Operating Margin of 23.0% in Sept 2026 (+0.0pp vs Mar 2026)
  • Earnings Per Share of ₹3.12 in Sept 2026 (-4.6% vs Mar 2026)

Marksans Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

MARKSANS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2026 Mar 2026 Jun 2026 Sept 2025 Mar 2025 QoQ YoY
Revenue (₹ Cr) 958 891 866 742 724 7.5% 29.1%
Net Profit (₹ Cr) 144 149 159 99 91 - -
EBITDA (₹ Cr) 232 231 238 166 142 - -
EPS (₹) 3.12 3.27 3.47 2.17 2.00 - -
Operating Margin (%) 23.0% 23.0% 25.0% 20.0% 18.0% - -

MARKSANS Share Price Trend — 1-Year Movement Across Quarterly Results

Marksans Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit MARKSANS share price screener.

Profitability Ratios

Profit Margin 15.0%
EBITDA Margin 24.2%
Operating Margin 23.0%
ROE (Annual) 18.9%

Balance Sheet Highlights

Total Assets ₹3,861 Cr
Total Equity ₹3,053 Cr
Current Assets ₹ Cr
Current Liabilities ₹281 Cr

Cash Flow Analysis

Operating Cash Flow ₹458 Cr
Investing Cash Flow ₹-249 Cr
Financing Cash Flow ₹-71 Cr
Net Cash Flow ₹138 Cr

Current Market Data

Current Price ₹299.05
Exchange NSE
Last Updated Nov 19, 2026

MARKSANS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Marksans Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1900.0 16,617 1,995 +10.6% - 12.0% 228.9
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11178.0 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4611.0 4,111 364 +27.7% +42.2% 8.9% 400.6
Apollo Hospitals
Sept 2026
₹126,832.45 Cr 8738.0 7,673 660 +15.2% - 8.6% 199.4
Laurus Labs
Sept 2026
₹125,946.78 Cr 2306.0 2,219 436 +21.7% - 19.6% 282.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores